advertisement
 

  Back to News Research News from 2015

Research News From 2015

    24 December 2015

  1. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
  2. The artificial pancreas: challenges and opportunities. Free full text available in PDF format.
  3. Toward Automation of Insulin Delivery - Management Solutions for Type 1 Diabetes.
  4. Islet Transplantation in Pediatric Patients: Current Indications and Future Perspectives.
  5. The Haptoglobin genotype predicts cardio-renal mortality in type 1 diabetes.
  6. The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes.
  7. Early Neurodegeneration of the Inner Retinal Layers in Type 1 Diabetes Mellitus.
  8. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes.

    16 December 2015

  9. Therapies to Preserve β-Cell Function in Type 1 Diabetes.
  10. Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review. Free full text available in HTML and PDF formats.
  11. Evidence of Extrapancreatic Glucagon Secretion in Man.

    9 December 2015

  12. Infant Growth and Risk of Childhood-Onset Type 1 Diabetes in Children From 2 Scandinavian Birth Cohorts See also Weight Gain in Infancy and Type 1 Diabetes Might Be Related.
  13. Reduced β-cell function in early preclinical type 1 diabetes.
  14. Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion.
  15. Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations.
  16. Substantial proportion of MODY among multiplex families participating in a Type 1 diabetes prediction programme.
  17. Saxagliptin co-therapy in C-peptide-negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia.

    1 December 2015

  18. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. See also End of daily injections for diabetes as scientists restore insulin production.
  19. Ketoacidosis at diagnosis in childhood-onset diabetes and the risk of retinopathy 20years later.
  20. Insulitis and characterisation of infiltrating T cells in surgical pancreatic tail resections from patients at onset of type 1 diabetes.
  21. The impact of having siblings - analysis of "hygiene theory" of chronic diseases in patients with type 1 diabetes in population of the Lodz region.
  22. Vitamin D status in youth with type 1 and type 2 diabetes enrolled in the Pediatric Diabetes Consortium (PDC) is not worse than in youth without diabetes.
  23. A Comparative Analysis of the Safety, Efficacy, and Cost of Islet Versus Pancreas Transplantation in Nonuremic Patients With Type 1 Diabetes.
  24. Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.
  25. Diabetic pancreas cells made to produce insulin by bone protein.

    25 November 2015

  26. Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. Free full text available in HTML and PDF (via link) formats.
  27. Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes.
  28. Bacillus Calmette-Guérin (BCG) Vaccination in Infancy and Risk of Childhood Diabetes.
  29. Artificial Pancreas Device Systems for the Closed-Loop Control of Type 1 Diabetes: What Systems Are in Development?
  30. Metabolic Control With the Bio-inspired Artificial Pancreas in Adults With Type 1 Diabetes: A 24-Hour Randomized Controlled Crossover Study.
  31. Successful Application of Closed-Loop Artificial Pancreas Therapy After Islet Autotransplantation.
  32. Immune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice. Free full text available in HTML and PDF formats.

    25 November 2015

  33. Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. Free full text available in HTML and PDF (via link) formats.
  34. Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes.
  35. Bacillus Calmette-Guérin (BCG) Vaccination in Infancy and Risk of Childhood Diabetes.
  36. Artificial Pancreas Device Systems for the Closed-Loop Control of Type 1 Diabetes: What Systems Are in Development?
  37. Metabolic Control With the Bio-inspired Artificial Pancreas in Adults With Type 1 Diabetes: A 24-Hour Randomized Controlled Crossover Study.
  38. Successful Application of Closed-Loop Artificial Pancreas Therapy After Islet Autotransplantation.
  39. Immune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice. Free full text available in HTML and PDF formats.

    17 November 2015

  40. Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies.
  41. Diet, Microbiota and Immune System in Type 1 Diabetes Development and Evolution. Free full text available in HTML and PDF formats.
  42. Coxsackievirus B5 Infection Induces Dysregulation of MicroRNAs Predicted to Target Known Type 1 Diabetes Risk Genes in Human Pancreatic Islets.
  43. Changing the Course of Disease in Type 1 Diabetes. Free full text available in HTML Reader format.
  44. No association between use of multivitamin supplement containing vitamin D during pregnancy and risk of Type 1 Diabetes in the child.
  45. Zinc and Other Metals Deficiencies and Risk of Type 1 Diabetes: An Ecological Study in the High Risk Sardinia Island. Free full text available in HTML and PDF formats.
  46. Hemoglobin A1c and Self-Monitored Average Glucose: Validation of the Dynamical Tracking eA1c Algorithm in Type 1 Diabetes.
  47. Protocol for systematic review of evidence on the determinants and influence of early glycaemic control in childhood-onset type 1 diabetes. Free full text available in HTML and PDF formats.
  48. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. See also Anti-VEGF Pharmacotherapy as an Alternative to Panretinal Laser Photocoagulation for Proliferative Diabetic Retinopathy.

    11 November 2015

  49. Association of Early Exposure of Probiotics and Islet Autoimmunity in the TEDDY Study. Free full text available in HTML and PDF via link (free membership required for access to PDF). See also A Glimpse of Microbial Power in Preventive Medicine and Infants at Risk of Type 1 Diabetes Benefit from Early Probiotics.
  50. A novel method to detect pressure-induced sensor attenuations (PISA) in an artificial pancreas. Free full text available in HTML and PDF formats.
  51. Postprandial capillary-venous glucose gradient in Type 1 diabetes: magnitude and clinical associations in a real-world setting.
  52. Evaluation of the Average Daily Risk Range as a Measure of Glycemic Variability in Youths with Type 1 Diabetes.
  53. Design and Evaluation of a Robust PID Controller for a Fully Implantable Artificial Pancreas. Free full text available in HTML and PDF formats.
  54. Lessons From Pancreas Transplantation in Type 1 Diabetes: Recurrence of Islet Autoimmunity.
  55. Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. Free full text available in HTML and PDF formats.

    4 November 2015

  56. Single- and Dual-hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes.
  57. Metabolic control after years of completing a clinical trial on sensor-augmented pump therapy.
  58. Efficacy and Safety of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, as Add-On to Insulin in Patients With Type 1 Diabetes.
  59. Variations in brain volume and growth in young children with type 1 diabetes.
  60. Gestational Age and Birth Weight and the Risk of Childhood Type 1 Diabetes: A Population-Based Cohort and Sibling Design Study.
  61. Vitamin D fortification and seasonality of birth in type 1 diabetic cases: D-tect study.

    27 October 2015

  62. Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring.
  63. Identification of Main Factors Explaining Glucose Dynamics During and Immediately After Moderate Exercise in Patients With Type 1 Diabetes.
  64. Rapidly rising incidence of Type 1 diabetes in children and adolescents aged 0-19 years in Zhejiang, China, 2007 to 2013.

    21 October 2015

  65. Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?
  66. In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus.
  67. Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.

    14 October 2015

  68. Immunoproteomic Profiling of Anti-Viral Antibodies in New-Onset Type 1 Diabetes Using Protein Arrays.
  69. Genetic sharing and heritability of paediatric age of onset autoimmune diseases. Free full text available in PDF format.

    7 October 2015

  70. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
  71. Exercise and the Development of the Artificial Pancreas: One of the More Difficult Series of Hurdles.
  72. Influence of remission and its duration on development of early microvascular complications in young adults with type 1 diabetes.
  73. Development of a Smartphone Application to Capture Carbohydrate, Lipid, and Protein Contents of Daily Food: Need for Integration in Artificial Pancreas for Patients With Type 1 Diabetes?
  74. Type 1 diabetes prevention: Insulin vaccine undergoes second trial.

    30 September 2015

  75. Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. Free full text available in PDF format.
  76. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Free full text available in PDF format.
  77. American Diabetes Association and JDRF Research Symposium: Diabetes and the Microbiom.
  78. Alternate Approaches for Pediatric Type 1 Diabetes Drug Development and Potential Regulatory Approval: A Perspective. Free full text available in PDF format.
  79. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Free full text available in HTML and PDF formats.
  80. Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes.
  81. Shared Genetic Basis for Type 1 Diabetes, Islet Autoantibodies, and Autoantibodies Associated With Other Immune-Mediated Diseases in Families With Type 1 Diabetes.
  82. Long-term function of alginate encapsulated islets.

    23 September 2015

  83. Home Use of an Artificial Beta Cell in Type 1 Diabetes. Free full text available in PDF format.
  84. Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the System's Fuzzy Logic Controller.
  85. Combining glucose monitoring and insulin delivery into a single device: current progress and ongoing challenges of the artificial pancreas.
  86. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes.
  87. EASD: Intranasal glucagon reverses hypoglycemia in children and adolescents.
  88. Efficacy and safety of canagliflozin: results of an 18-week phase 2 study in patients with type 1 diabetes. See also Invokana lowers HbA1c and aids weight loss in adults with type 1 diabetes, study finds and First Data on SGLT2 Inhibitor Canagliflozin in Type 1 Diabetes.
  89. Update on ketoacidosis with SGLT2 inhibitors.

    18 September 2015

  90. Cathelicidin antimicrobial peptide: a novel regulator of islet function, islet regeneration and selected gut bacteria.
  91. Naltrexone for treatment of impaired awareness of hypoglycemia in type 1 diabetes: A randomized clinical trial.

    9 September 2015

  92. Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System.
  93. Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels.
  94. After 6 years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level.
  95. Elevated Serum Levels of Soluble TNF Receptors and Adhesion Molecules Are Associated with Diabetic Retinopathy in Patients with Type-1 Diabetes. Free full text available in HTML and PDF formats.
  96. Risk factors associated with the development of retinopathy 10 yr after the diagnosis of juvenile-onset type 1 diabetes in Taiwan: a cohort study from the CGJDES.
  97. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Free full text available in HTML and PDF formats.
  98. Secular trends of body mass index in North Indian children with Type 1 Diabetes do not support the Accelerator Hypothesis.
  99. Real-time estimation of plasma insulin concentration from continuous glucose monitor measurements.

    2 September 2015

  100. Unsupervised overnight closed loop insulin delivery during free living: analysis of randomised cross-over home studies in adults and adolescents with type 1 diabetes.
  101. Predictive factors for prolonged remission after autologous hematopoietic stem cell transplantation in young patients with type 1 diabetes mellitus.
  102. Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community.
  103. Insulin-Producing Endocrine Cells Differentiated In Vitro From Human Embryonic Stem Cells Function in Macroencapsulation Devices In Vivo.
  104. Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device. Free full text PDF available via link on journal web page.

    26 August 2015

  105. Caesarean section per se does not increase the risk of offspring developing type 1 diabetes: a Swedish population-based study.
  106. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression.
  107. Proteomic Analysis of Disease Stratified Human Pancreas Tissue Indicates Unique Signature of Type 1 Diabetes. Free full text available in HTML and PDF formats.

    19 August 2015

  108. Type 1 Diabetes Modifies Brain Activation in Young Patients While Performing Visuospatial Working Memory Tasks.
  109. Extreme Beta-Cell Deficiency in Pancreata of Dogs with Canine Diabetes. Free full text available in PDF format. See also Penn/Baylor Med Study Describes Underlying Cause of Diabetes in Dogs.
  110. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice.

    12 August 2015

  111. Feasibility of screening for T1D and celiac disease in a pediatric clinic settin.
  112. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
  113. Influenza A virus antibodies show no association with pancreatic islet autoantibodies in children genetically predisposed to type 1 diabetes.
  114. Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathy. Free full text available in HTML and PDF formats.
  115. Kidney Dysfunction in Adult Offspring Exposed In Utero to Type 1 Diabetes Is Associated with Alterations in Genome-Wide DNA Methylation. Free full text available in HTML and PDF formats.
  116. Urinary MicroRNA Profiling Predicts the Development of Microalbuminuria in Patients with Type 1 Diabetes. Free full text available in HTML Reader format.

    5 August 2015

  117. Artificial Pancreas Updates From ADA (July 2015).
  118. Multisite Study of an Implanted Continuous Glucose Sensor Over 90 Days in Patients With Diabetes Mellitus.
  119. Regular peaks and troughs in the Australian incidence of childhood type 1 diabetes mellitus (2000-2011).

    29 July 2015

  120. Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention.
  121. Adjustment of Open-Loop Settings to Improve Closed-Loop Results in Type 1 Diabetes: A Multicenter Randomized Trial.
  122. Infant Feeding and Timing of Complementary Foods in the Development of Type 1 Diabetes.

    22 July 2015

  123. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
  124. Long-Term Immunosuppression After Solitary Islet Transplantation Is Associated With Preserved C-Peptide Secretion for More Than a Decade.
  125. Trends in Incidence Rates during 1999-2008 and Prevalence in 2008 of Childhood Type 1 Diabetes Mellitus in GERMANY - Model-Based National Estimates. Free full text available in HTML and PDF formats.
  126. Explaining the increased mortality in type 1 diabetes. Free full text available in HTML and PDF formats.
  127. An observational study of patient characteristics and mortality following hypoglycemia in the community. Free full text available in HTML and PDF formats.
  128. Long-Term Home Study on Nocturnal Hypoglycemic Alarms Using a New Fully Implantable Continuous Glucose Monitoring System in Type 1 Diabetes.
  129. Alpha-Lipoic Acid and Antioxidant Diet Help to Improve Endothelial Dysfunction in Adolescents with Type 1 Diabetes: A Pilot Trial. Free full text available in HTML and PDF formats.

    15 July 2015

  130. Sensitivity of the Predictive Hypoglycemia Minimizer System to the Algorithm Aggressiveness Factor.
  131. Early Detection of Physical Activity for People With Type 1 Diabetes Mellitus.
  132. Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes. See also Inhaled Formoterol Prevents Hypoglycemia in Diabetes Study.
  133. Clinically Relevant Cognitive Impairment in Middle-Aged Adults With Childhood-Onset Type 1 Diabetes.
  134. The Role of Markers of Low-Grade Inflammation for the Early Time Course of Glycemic Control, Glucose Disappearance Rate, and beta-Cell Function in Recently Diagnosed Type 1 and Type 2 Diabetes.
  135. Dietary intake of soluble fiber and risk of islet autoimmunity by 5 y of age: results from the TEDDY study.
  136. Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes.

    1 July 2015

  137. Parasitic helminths and their beneficial impact on type 1 and type 2 diabetes.
  138. Nocturnal Glucose Metabolism in Type 1 Diabetes: A Study Comparing Single Versus Dual Tracer Approaches.
  139. Compromised immune response in infants at risk for type 1 diabetes born by Caesarean Section.
  140. Maternal VDR variants rather than 25-hydroxyvitamin D concentration during early pregnancy are associated with type 1 diabetes in the offspring.
  141. Ethnic differences in the incidence of type 1 diabetes in Norway: a register-based study using data from the period 2002-200.
  142. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.

    24 June 2015

  143. Alterations in Intestinal Microbiota Correlate with Susceptibility to Type 1 Diabetes.
  144. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. See also Smart insulin patch could replace painful injections for diabetes.
  145. Insulin Delivery into the Peripheral Circulation: a Key Contributor to Hypoglycemia in Type 1 Diabetes.
  146. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
  147. Long-Term Control of Diabetes in Immunosuppressed Nonhuman Primates (NHP) by the Transplantation of Adult Porcine Islets.
  148. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
  149. A run on the biobank: what have we learned about type 1 diabetes from the nPOD tissue repository?
  150. Lipoprotein subfraction cholesterol distribution is more atherogenic in insulin resistant adolescents with type 1 diabetes.
  151. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes.

    17 June 2015

  152. Efficacy of dual-hormone artificial pancreas to alleviate the carbohydrate-counting burden of type 1 diabetes: A randomized crossover trial.
  153. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. See also Which artificial pancreas system is the best for children with type 1 diabetes?
  154. Artificial Pancreas (AP) Technology Take the Stage at the 75th Annual American Diabetes Association (ADA) Conference.
  155. Hope Ahead? Varying Approaches Progress Artificial Pancreas.
  156. Bionic pancreas effective therapy in preadolescent summer camp setting.
  157. Non-HLA gene effects on the disease process of type 1 diabetes: From HLA susceptibility to overt disease.
  158. Alpha-1 antitrypsin therapy is safe and well tolerated in children and adolescents with recent onset type 1 diabetes mellitus.
  159. Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema.
  160. Family history and ethnicity influencing clinical presentation of type 1 diabetes in childhood.
  161. Parents' experiences 12 years after newborn screening for genetic susceptibility to type 1 diabetes and their attitudes to whole-genome sequencing in newborns.
  162. Extreme Beta-Cell Deficiency in Pancreata of Dogs with Canine Diabetes. Free full text available in HTML and PDF formats.

    10 June 2015

  163. Sugar intake is associated with progression from islet autoimmunity to type 1 diabetes: the Diabetes Autoimmunity Study in the Young.
  164. Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis. Free full text available in PDF format.
  165. Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp. Free full text available in PDF format.
  166. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Free full text available in PDF format.
  167. Glucagon - the new 'insulin' in the pathophysiology of diabetes.

    3 June 2015

  168. Fabrication of three-dimensional bioplotted hydrogel scaffolds for islets of Langerhans transplantation. See also 3D-printed scaffolds may make for improved diabetes treatment.
  169. Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.
  170. Gestational and Early Infancy Exposure to Margarine Fortified with Vitamin D through a National Danish Programme and the Risk of Type 1 Diabetes: The D-Tect Study. Free full text available in HTML and PDF formats.
  171. Vitamin D levels at birth and risk of type 1 diabetes in childhood: a case-control study.

    27 May 2015

  172. Association between hypoglycaemia and impaired hypoglycaemia awareness and mortality in people with Type 1 diabetes mellitus.
  173. Infrared thermographic assessment of changes in skin temperature during hypoglycaemia in patients with type 1 diabetes.
  174. Magnetic resonance imaging reveals altered distribution of hepatic fat in children with type 1 diabetes compared to controls.
  175. Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial.
  176. Treatment of diabetes with encapsulated pig islets: an update on current developments. Free full text available in HTML and PDF formats.
  177. Behavioral economics survey of patients with type 1 and type 2 diabetes. Free full text available in HTML and PDF formats.

    20 May 2015

  178. Stem cells for the cell and molecular therapy of type 1 diabetes mellitus (T1D): the gap between dream and reality. Free full text available in HTML and PDF formats.
  179. Efficacy and Safety of LY2963016 Insulin Glargine Compared with Insulin Glargine (Lantus®) in Patients with Type 1 Diabetes in a Randomised Controlled Trial (The ELEMENT 1 Study).
  180. Glycated albumin and the risk of micro- and macrovascular complications in subjects with Type 1 Diabetes. Free full text available in HTML and PDF formats.
  181. Lipid peroxidation and antioxidant protection in girls with type 1 diabetes mellitus during reproductive system development. Free full text available in HTML and PDF formats.
  182. Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. Free full text available in HTML and PDF formats.

    13 May 2015

  183. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.
  184. A model for the role of gut bacteria in the development of autoimmunity for type 1 diabetes.

    6 May 2015

  185. Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. See also Experimental 'Smart' Insulin Shows Promise in Mice: Study.
  186. In-silico Closed Loop Control Validation Studies for Optimal Insulin Delivery in Type 1 Diabetes.
  187. Clinical results of islet transplantation.

    29 April 2015

  188. Clinical Results of an Automated Artificial Pancreas Using Technosphere Inhaled Insulin to Mimic First-Phase Insulin Secretion.
  189. Type 1 diabetes: A predictable disease. Free full text available in HTML and PDF formats.
  190. Efficacy of a long-acting c-peptide analogue against peripheral neuropathy in streptozotocin-diabetic mice.
  191. Glycemia, Hypoglycemia, and Costs of Simultaneous Islet-Kidney or Islet After Kidney Transplantation Versus Intensive Insulin Therapy and Waiting List for Islet Transplantation.
  192. White matter hyperintensities in middle-aged adults with childhood-onset type 1 diabetes.
  193. Living Donor Kidney Transplantation Preceding Pancreas Transplantation Reduces Mortality in Type 1 Diabetics With End-stage Renal Disease.
  194. Straylight, lens yellowing and aberrations of eyes in Type 1 diabetes. Free full text available in HTML and PDF formats.

    22 April 2015

  195. A prevascularized subcutaneous device-less site for islet and cellular transplantation.
  196. Effects of High-Dose Oral Insulin on Immune Responses in Children at High Risk for Type 1 Diabetes.
  197. Daycare attendance, breastfeeding, and the development of type 1 diabetes: the diabetes autoimmunity study in the young. Free full text available in HTML and PDF formats.
  198. Environmental Trigger(s) of Type 1 Diabetes: Why So Difficult to Identify? Free full text available in HTML and PDF formats.
  199. Can Exposure to Environmental Chemicals Increase the Risk of Diabetes Type 1 Development? Free full text available in HTML and PDF formats.
  200. Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications. Free full text available in HTML and PDF formats.
  201. Computer Vision-Based Carbohydrate Estimation for Type 1 Diabetic Patients Using Smartphones.
  202. New technologies in diabetology : How far are we from a closed loop?
  203. A method for reporting and classifying acute infectious diseases in a prospective study of young children: TEDDY. Free full text available in HTML and PDF formats.
  204. Modelling endogenous insulin concentration in type 2 diabetes during closed-loop insulin delivery. Free full text available in HTML and PDF formats.
  205. Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). Free full text available in HTML and PDF formats.

    15 April 2015

  206. Experience of a serious life event increases the risk for childhood type 1 diabetes: the ABIS population-based prospective cohort study. See also Serious life events in childhood can triple risk of developing type 1 diabetes.
  207. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. Free full text available in HTML and PDF formats.
  208. Continuous Intraperitoneal Insulin Infusion Versus Subcutaneous Insulin Therapy in the Treatment of Type 1 Diabetes: Effects on Glycemic Variability.
  209. Assessment of the relationship between hypoglycaemia awareness and autonomic function following islet cell/pancreas transplantation.
  210. Corneal Confocal Microscopy Detects Neuropathy in Patients with Type 1 Diabetes without Retinopathy or Microalbuminuria. Free full text available in HTML and PDF formats.
  211. Quantification of Diabetes Comorbidity Risks across Life Using Nation-Wide Big Claims Data. Free full text available in HTML and PDF formats.
  212. Distinct methylation patterns in genes that affect mitochondrial function are associated with kidney disease in blood-derived DNA from individuals with Type 1 diabetes.

    8 April 2015

  213. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study will add to the knowledge of the use of GLP-1 receptor agonists in people with type 1 diabetes.
  214. Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
  215. Perinatal and childhood risk factors for early-onset type 1 diabetes: a population-based case-control study in Taiwan.
  216. Lower serum 25 (OH) D concentrations in type 1 diabetes: A meta-analysis.

    2 April 2015

  217. Validity of animal models of type 1 diabetes, and strategies to enhance their utility in translational research.
  218. Bioengineered stem cells as an alternative for islet cell transplantation. Free full text available in HTML and PDF formats.
  219. Epidemiologic Features of Type 1 Diabetic Patients between 0 and 18 Years of Age in İstanbul City.
  220. Low mean temperature rather than few sunshine hours are associated with an increased incidence of type 1 diabetes in children.

    25 March 2015

  221. Less Is More: The Detrimental Consequences of Immunosuppressive Therapy in the Treatment of Type-1 Diabetes.

    18 March 2015

  222. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes.
  223. A Reassessment of the Survival Advantage of Simultaneous Kidney-Pancreas Versus Kidney-Alone Transplantation.

    11 March 2015

  224. An economic analysis of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of new onset type 1 diabetes.

    4 March 2015

  225. Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes.
  226. Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population. Free full text available in HTML and PDF formats.

    25 February 2015

  227. T1D Exchange Presents Data on New Form of Glucagon "Rescue" Treatment for Severe Hypoglycemia.
  228. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway.
  229. Effects of sitagliptin on counterregulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double blind placebo-controlled cross-over study.
  230. The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes.
  231. Microfabricated microporous membranes reduce the host immune response and prolong the functional lifetime of a closed-loop insulin delivery implant in a type 1 diabetic rat model.
  232. In Vivo Performance and Biocompatibility of a Subcutaneous Implant for Real-Time Glucose-Responsive Insulin Delivery.
  233. Long-term cultured neonatal islet cell clusters demonstrate better outcomes for reversal of diabetes: in vivo and molecular profiles.

    11 February 2015

  234. Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. See also Engineered insulin could offer better diabetes control, 'Smart' insulin hope for diabetes, and 'Smart' insulin may ease burden of type 1 diabetes patients, research suggests.
  235. Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY).
  236. Insulin detemir is transported from blood to cerebrospinal fluid and has prolonged central anorectic action relative to NPH insulin.
  237. Glycemic Control in Simultaneous Islet-Kidney Versus Pancreas-Kidney Transplantation in Type 1 Diabetes: A Prospective 13-Year Follow-up.
  238. Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients.
  239. C-peptide: New findings and therapeutic possibilities.
  240. CD4+ T-cell proliferation responses to wheat polypeptide stimulation in children at different stages of type 1 diabetes autoimmunity.
  241. Gut microbial markers are associated with diabetes onset, regulatory imbalance, and IFN-γ level in NOD Mice.

    6 February 2015

  242. Beta Cell death and dysfunction during type 1 diabetes development in at-risk individuals.
  243. Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want?
  244. Mesenchymal stem cells derived in vitro transdifferentiated insulin-producing cells: A new approach to treat type 1 diabetes. Free full text available in HTML format.
  245. The incidence of type 1 diabetes is still increasing in The Netherlands, but has stabilised in children under five (Young DUDEs-1).
  246. Diabetes in rats treated with engineered probiotic and Behind the headlines: a probiotic cure for diabetes? report on Engineered Commensal Bacteria Reprogram Intestinal Cells Into Glucose-Responsive Insulin-Secreting Cells for the Treatment of Diabetes, previously reported.

    28 January 2015

  247. Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes.
  248. Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting.
  249. Engineered Commensal Bacteria Reprogram Intestinal Cells Into Glucose-Responsive Insulin-Secreting Cells for the Treatment of Diabetes.
  250. Beta-cell destruction and preservation in childhood and adult onset type 1 diabetes.
  251. Bariatric surgery and diabetes: Implications of type 1 versus insulin-requiring type 2.
  252. The advanced glycation end product methylglyoxal-derived hydroimidazolone-1 and early signs of atherosclerosis in childhood diabetes. Free full text available in HTML and PDF formats.
  253. Prevalence and incidence of clinically recognized cases of Type 1 diabetes in children and adolescents in Rwanda, Africa.

    21 January 2015

  254. Multinight "Bedside" Closed-Loop Control for Patients with Type 1 Diabetes.
  255. Performance and Acceptability of a Combined Device for Insulin Infusion and Glucose Sensing in the Home Setting.
  256. Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing Type 1 Diabetes.
  257. Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual beta-Cell Function in Recent-Onset Type 1 Diabetes.

    14 January 2014

  258. Maternal intake of fatty acids and their food sources during lactation and the risk of preclinical and clinical type 1 diabetes in the offspring.
  259. Maternal smoking during pregnancy and offspring type 1 diabetes mellitus risk: accounting for HLA haplotype.
  260. An increasing incidence of type 1 diabetes mellitus in Romanian children aged 0 to 17 years.
  261. Maturity-onset diabetes of the young (MODY): an update.
  262. Uncovering the emotional aspects of working on a clinical trial: a qualitative study of the experiences and views of staff involved in a type 1 diabetes trial. Free full text available in PDF format.

    7 January 2014

  263. Neutrophil gelatinase-associated lipocalin and Cathepsin L as early predictors of kidney dysfunction in children with type 1 diabetes.

[ Current Research News | News from 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 ]



                 
  Back to News Return to Top

Last Updated: Wednesday January 13, 2016 20:30:02
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2017. Comments and Feedback.